Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
BBLG 
Bone Biologics Corp (BBLG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/25/2026: BBLG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22.25
1 Year Target Price $22.25
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.05M USD | Price to earnings Ratio - | 1Y Target Price 22.25 |
Price to earnings Ratio - | 1Y Target Price 22.25 | ||
Volume (30-day avg) 1 | Beta 0.41 | 52 Weeks Range 1.11 - 6.75 | Updated Date 02/25/2026 |
52 Weeks Range 1.11 - 6.75 | Updated Date 02/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.68% | Return on Equity (TTM) -80.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -4002488 | Price to Sales(TTM) - |
Enterprise Value -4002488 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.13 | Shares Outstanding 1795260 | Shares Floating 1787397 |
Shares Outstanding 1795260 | Shares Floating 1787397 | ||
Percent Insiders 0.04 | Percent Institutions 2.85 |
Upturn AI SWOT
Bone Biologics Corp
Company Overview
History and Background
Bone Biologics Corp. was founded in 2007 with the goal of developing and commercializing novel bone graft materials for orthopedic and spinal applications. A significant milestone was the development of their proprietary NEUROCERAu00ae bone graft material, which aims to enhance bone regeneration. The company has focused on advancing its technology through preclinical and clinical studies, seeking regulatory approvals and strategic partnerships.
Core Business Areas
- Bone Graft Material Development: Bone Biologics Corp. is primarily focused on the research, development, and commercialization of advanced bone graft materials. Their core technology aims to accelerate and improve the healing process for bone defects and fractures.
Leadership and Structure
The leadership team typically consists of a CEO, Chief Scientific Officer, and a Board of Directors with expertise in orthopedics, biomaterials, and business development. The organizational structure is generally lean, characteristic of a development-stage biotechnology company.
Top Products and Market Share
Key Offerings
- NEUROCERAu00ae Bone Graft: NEUROCERAu00ae is Bone Biologics Corp.'s flagship product candidate. It is a bio-interactive bone graft material designed to stimulate bone healing. Specific market share data is not publicly available as the product is still in development and seeking commercialization. Competitors in the bone graft market include companies like Synthesys (Zimmer Biomet), MasterGraft (NuVasive), and various others offering demineralized bone matrix (DBM), allografts, and synthetic bone substitutes.
Market Dynamics
Industry Overview
The bone graft market is a segment of the larger orthopedic and regenerative medicine industries. It is driven by an aging population, increasing incidence of orthopedic injuries and degenerative diseases, and advancements in biomaterial technology. The market is competitive, with established players and emerging companies vying for market share.
Positioning
Bone Biologics Corp. positions itself as an innovator in the bone graft space, focusing on proprietary technology that offers potential advantages in bone regeneration. Their competitive advantage lies in the unique properties of NEUROCERAu00ae and its potential to improve patient outcomes.
Total Addressable Market (TAM)
The global bone graft market is substantial and projected to grow significantly. Estimates vary, but it is generally in the billions of dollars. Bone Biologics Corp. aims to capture a portion of this market with its innovative product, but its current market share is negligible as it is in the development phase.
Upturn SWOT Analysis
Strengths
- Proprietary NEUROCERAu00ae technology
- Focus on a growing medical need
- Experienced leadership team (assumed)
Weaknesses
- Development-stage company with no commercialized products
- Reliance on clinical trial success and regulatory approvals
- Limited financial resources compared to larger competitors
- Need for significant capital investment for commercialization
Opportunities
- Growing demand for effective bone regeneration solutions
- Potential for strategic partnerships or acquisitions
- Expansion into different orthopedic and spinal applications
- Advancements in regenerative medicine
Threats
- Competition from established players with existing market share
- Regulatory hurdles and lengthy approval processes
- Unforeseen clinical trial outcomes
- Reimbursement challenges
- Technological obsolescence
Competitors and Market Share
Key Competitors
- Zimmer Biomet Holdings, Inc. (ZBH)
- NuVasive, Inc. (NUVA)
- Stryker Corporation (SYK)
- Medtronic plc (MDT)
Competitive Landscape
Bone Biologics Corp. faces formidable competition from large, well-established orthopedic companies that have extensive product portfolios, significant R&D budgets, and established distribution channels. Its advantage lies in its specialized focus on a potentially disruptive technology, but it must overcome the market dominance of its larger rivals.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by the progression of its technology through research and development phases, securing intellectual property, and seeking funding. Revenue growth is nascent and contingent on future commercialization.
Future Projections: Future growth projections are highly dependent on the successful clinical development, regulatory approval, and market adoption of NEUROCERAu00ae. Analyst projections are typically not widely available for such early-stage companies. Potential future revenue would be tied to sales of its bone graft products.
Recent Initiatives: Recent initiatives likely involve advancing NEUROCERAu00ae through preclinical and clinical studies, seeking strategic partnerships, and potentially pursuing regulatory filings.
Summary
Bone Biologics Corp. is a development-stage company focused on innovative bone graft technology. Its strength lies in its proprietary NEUROCERAu00ae product. However, it faces significant weaknesses due to its lack of commercialized products and reliance on future approvals. Opportunities exist in a growing market, but threats from established competitors and regulatory hurdles are substantial. The company needs to successfully navigate clinical trials and secure funding for commercialization to achieve its potential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases (when available)
- SEC filings (e.g., 10-K, 10-Q, S-1 for publicly traded companies)
- Industry analysis reports (general market data)
- Financial news outlets
Disclaimers:
This JSON output is based on publicly available information and general industry knowledge. It is not an exhaustive analysis and should not be considered investment advice. Specific financial data, market share percentages, and competitor information for development-stage companies can be highly variable and may require access to proprietary databases or direct company disclosures. The market share data provided is illustrative and based on general industry knowledge. Bone Biologics Corp. is a speculative investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bone Biologics Corp
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2016-03-31 | CEO & President Mr. Jeffrey Frelick | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.bonebiologics.com |
Full time employees 2 | Website https://www.bonebiologics.com | ||
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.